Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335130 | 0.96 | TOP2A (0.49) | TOP2A | |
| SCHEMBL910258 | 0.93 | TOP2A (0.39) | TOP2A | |
| SCHEMBL910118 | 0.93 | TOP2A (0.39) | TOP2A | |
| SCHEMBL910127 | 0.89 | TOP2A (0.42) | TOP2A | |
| SCHEMBL910202 | 0.89 | TOP2A (0.42) | TOP2A | |
| SCHEMBL19470007 | 0.85 | TOP2A (0.34) | TOP2A | |
| SCHEMBL335601 | 0.85 | TOP2A (0.34) | TOP2A | |
| SCHEMBL1312958 | 0.81 | TOP2A (0.33) | TOP2A | |
| SCHEMBL3327648 | 0.80 | TOP2A (0.53) | TOP2A | |
| SCHEMBL12746439 | 0.79 | TOP2A (0.51) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | TOP2A 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.